Global Immunosuppressant Drugs
Global Immunosuppressant Drugs

Immunosuppressant Drugs Comprehensive Study by End-users (Hospitals, Clinics, Others), Indication (Organ Transplantation, Autoimmune Disorders, Non-autoimmune Inflammatory Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, MTOR Inhibitors, Anti-Proliferative Agents, Others) Players and Region - Global Market Outlook to 2026

Immunosuppressant Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 214 Pages 200 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Immunosuppressant Drugs Market?

Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body’s immune system. These drugs used to treat autoimmune diseases. The autoimmune diseases treated with these drugs include psoriasis, lupus, rheumatoid arthritis, Crohn’s disease, multiple sclerosis and alopecia areata. These drugs are prescribed depending on whether the patient has an organ transplant, an autoimmune disorder, or another condition. The factors such as Increased Prevalence of Autoimmune Disorders such as Arthritis and Increased Number of DIagnostic Centres and Hospitals are driving the global immunosuppressant drugs market.

The market study is being classified and major geographies with country level break-up.

Novartis International AG (Switzerland), Astellas Pharma Inc. (Japan), Roche Holding AG (Switzerland), Pfizer (United States), Sanofi S.A. (France), Allergan, Inc. (United States), Bristol-Myers Squibb (United States), AbbVie Inc. (United States), Veloxis Pharmaceuticals A/S (Denmark) and GlaxoSmithKline plc (United Kingdom) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Immunosuppressant Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Immunosuppressant Drugs market by Type, Application and Region.

On the basis of geography, the market of Immunosuppressant Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Autoimmune Disorders such as Arthritis
  • Increased Number of DIagnostic Centres and Hospitals
  • Rise in the Healthcare Infrastructure in Developing Regions

Market Trend
  • Rise in the Number of Online Pharmacies
  • Increased Research and Development Activities

Restraints
  • Side Effects of the Immunosuppressant Drugs

Opportunities
  • Growth in the Healthcare Industry
  • Increasing Number of Target Population
  • Huge Investments by Major Players in the Healthcare Sector

Challenges
  • Stringent Government Rules and Regulations about Drugs


In January 2020, Novartis has successfully completed the acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran.


Key Target Audience
Immunosuppressant Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By End-users
  • Hospitals
  • Clinics
  • Others

By Indication
  • Organ Transplantation
  • Autoimmune Disorders
  • Non-autoimmune Inflammatory Diseases

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Drug Class
  • Corticosteroids
  • Monoclonal Antibodies (mAbs)
  • Calcineurin Inhibitors
  • MTOR Inhibitors
  • Anti-Proliferative Agents
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Autoimmune Disorders such as Arthritis
      • 3.2.2. Increased Number of DIagnostic Centres and Hospitals
      • 3.2.3. Rise in the Healthcare Infrastructure in Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations about Drugs
    • 3.4. Market Trends
      • 3.4.1. Rise in the Number of Online Pharmacies
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immunosuppressant Drugs, by End-users, Indication, Distribution Channel, Drug Class and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Immunosuppressant Drugs (Value)
      • 5.2.1. Global Immunosuppressant Drugs by: End-users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Immunosuppressant Drugs by: Indication (Value)
        • 5.2.2.1. Organ Transplantation
        • 5.2.2.2. Autoimmune Disorders
        • 5.2.2.3. Non-autoimmune Inflammatory Diseases
      • 5.2.3. Global Immunosuppressant Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Immunosuppressant Drugs by: Drug Class (Value)
        • 5.2.4.1. Corticosteroids
        • 5.2.4.2. Monoclonal Antibodies (mAbs)
        • 5.2.4.3. Calcineurin Inhibitors
        • 5.2.4.4. MTOR Inhibitors
        • 5.2.4.5. Anti-Proliferative Agents
        • 5.2.4.6. Others
      • 5.2.5. Global Immunosuppressant Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Immunosuppressant Drugs (Volume)
      • 5.3.1. Global Immunosuppressant Drugs by: End-users (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Immunosuppressant Drugs by: Indication (Volume)
        • 5.3.2.1. Organ Transplantation
        • 5.3.2.2. Autoimmune Disorders
        • 5.3.2.3. Non-autoimmune Inflammatory Diseases
      • 5.3.3. Global Immunosuppressant Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online
        • 5.3.3.4. Others
      • 5.3.4. Global Immunosuppressant Drugs by: Drug Class (Volume)
        • 5.3.4.1. Corticosteroids
        • 5.3.4.2. Monoclonal Antibodies (mAbs)
        • 5.3.4.3. Calcineurin Inhibitors
        • 5.3.4.4. MTOR Inhibitors
        • 5.3.4.5. Anti-Proliferative Agents
        • 5.3.4.6. Others
      • 5.3.5. Global Immunosuppressant Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Immunosuppressant Drugs (Price)
  • 6. Immunosuppressant Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Allergan, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Veloxis Pharmaceuticals A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Immunosuppressant Drugs Sale, by End-users, Indication, Distribution Channel, Drug Class and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Immunosuppressant Drugs (Value)
      • 7.2.1. Global Immunosuppressant Drugs by: End-users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Immunosuppressant Drugs by: Indication (Value)
        • 7.2.2.1. Organ Transplantation
        • 7.2.2.2. Autoimmune Disorders
        • 7.2.2.3. Non-autoimmune Inflammatory Diseases
      • 7.2.3. Global Immunosuppressant Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Immunosuppressant Drugs by: Drug Class (Value)
        • 7.2.4.1. Corticosteroids
        • 7.2.4.2. Monoclonal Antibodies (mAbs)
        • 7.2.4.3. Calcineurin Inhibitors
        • 7.2.4.4. MTOR Inhibitors
        • 7.2.4.5. Anti-Proliferative Agents
        • 7.2.4.6. Others
      • 7.2.5. Global Immunosuppressant Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Immunosuppressant Drugs (Volume)
      • 7.3.1. Global Immunosuppressant Drugs by: End-users (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Immunosuppressant Drugs by: Indication (Volume)
        • 7.3.2.1. Organ Transplantation
        • 7.3.2.2. Autoimmune Disorders
        • 7.3.2.3. Non-autoimmune Inflammatory Diseases
      • 7.3.3. Global Immunosuppressant Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online
        • 7.3.3.4. Others
      • 7.3.4. Global Immunosuppressant Drugs by: Drug Class (Volume)
        • 7.3.4.1. Corticosteroids
        • 7.3.4.2. Monoclonal Antibodies (mAbs)
        • 7.3.4.3. Calcineurin Inhibitors
        • 7.3.4.4. MTOR Inhibitors
        • 7.3.4.5. Anti-Proliferative Agents
        • 7.3.4.6. Others
      • 7.3.5. Global Immunosuppressant Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Immunosuppressant Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immunosuppressant Drugs: by End-users(USD Million)
  • Table 2. Immunosuppressant Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 3. Immunosuppressant Drugs Clinics , by Region USD Million (2015-2020)
  • Table 4. Immunosuppressant Drugs Others , by Region USD Million (2015-2020)
  • Table 5. Immunosuppressant Drugs: by Indication(USD Million)
  • Table 6. Immunosuppressant Drugs Organ Transplantation , by Region USD Million (2015-2020)
  • Table 7. Immunosuppressant Drugs Autoimmune Disorders , by Region USD Million (2015-2020)
  • Table 8. Immunosuppressant Drugs Non-autoimmune Inflammatory Diseases , by Region USD Million (2015-2020)
  • Table 9. Immunosuppressant Drugs: by Distribution Channel(USD Million)
  • Table 10. Immunosuppressant Drugs Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Immunosuppressant Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Immunosuppressant Drugs Online , by Region USD Million (2015-2020)
  • Table 13. Immunosuppressant Drugs Others , by Region USD Million (2015-2020)
  • Table 14. Immunosuppressant Drugs: by Drug Class(USD Million)
  • Table 15. Immunosuppressant Drugs Corticosteroids , by Region USD Million (2015-2020)
  • Table 16. Immunosuppressant Drugs Monoclonal Antibodies (mAbs) , by Region USD Million (2015-2020)
  • Table 17. Immunosuppressant Drugs Calcineurin Inhibitors , by Region USD Million (2015-2020)
  • Table 18. Immunosuppressant Drugs MTOR Inhibitors , by Region USD Million (2015-2020)
  • Table 19. Immunosuppressant Drugs Anti-Proliferative Agents , by Region USD Million (2015-2020)
  • Table 20. Immunosuppressant Drugs Others , by Region USD Million (2015-2020)
  • Table 21. South America Immunosuppressant Drugs, by Country USD Million (2015-2020)
  • Table 22. South America Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 23. South America Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 24. South America Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 25. South America Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 26. Brazil Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 27. Brazil Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 28. Brazil Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. Brazil Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 30. Argentina Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 31. Argentina Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 32. Argentina Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 33. Argentina Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 34. Rest of South America Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 35. Rest of South America Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 36. Rest of South America Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 37. Rest of South America Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 38. Asia Pacific Immunosuppressant Drugs, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 40. Asia Pacific Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 41. Asia Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 42. Asia Pacific Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 43. China Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 44. China Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 45. China Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 46. China Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 47. Japan Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 48. Japan Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 49. Japan Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 50. Japan Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 51. India Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 52. India Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 53. India Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. India Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 55. South Korea Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 56. South Korea Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 57. South Korea Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 58. South Korea Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 59. Taiwan Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 60. Taiwan Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 61. Taiwan Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 62. Taiwan Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 63. Australia Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 64. Australia Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 65. Australia Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. Australia Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 71. Europe Immunosuppressant Drugs, by Country USD Million (2015-2020)
  • Table 72. Europe Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 73. Europe Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 74. Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 75. Europe Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 76. Germany Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 77. Germany Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 78. Germany Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Germany Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 80. France Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 81. France Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 82. France Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 83. France Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 84. Italy Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 85. Italy Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 86. Italy Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 87. Italy Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 88. United Kingdom Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 89. United Kingdom Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 90. United Kingdom Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 91. United Kingdom Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 92. Netherlands Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 93. Netherlands Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 94. Netherlands Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 95. Netherlands Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 96. Rest of Europe Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 97. Rest of Europe Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 98. Rest of Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 99. Rest of Europe Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 100. MEA Immunosuppressant Drugs, by Country USD Million (2015-2020)
  • Table 101. MEA Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 102. MEA Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 103. MEA Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 104. MEA Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 105. Middle East Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 106. Middle East Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 107. Middle East Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 108. Middle East Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 109. Africa Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 110. Africa Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 111. Africa Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 112. Africa Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 113. North America Immunosuppressant Drugs, by Country USD Million (2015-2020)
  • Table 114. North America Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 115. North America Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 116. North America Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 117. North America Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 118. United States Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 119. United States Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 120. United States Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 121. United States Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 122. Canada Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 123. Canada Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 124. Canada Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 125. Canada Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 126. Mexico Immunosuppressant Drugs, by End-users USD Million (2015-2020)
  • Table 127. Mexico Immunosuppressant Drugs, by Indication USD Million (2015-2020)
  • Table 128. Mexico Immunosuppressant Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 129. Mexico Immunosuppressant Drugs, by Drug Class USD Million (2015-2020)
  • Table 130. Immunosuppressant Drugs Sales: by End-users(K Units)
  • Table 131. Immunosuppressant Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 132. Immunosuppressant Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 133. Immunosuppressant Drugs Sales Others , by Region K Units (2015-2020)
  • Table 134. Immunosuppressant Drugs Sales: by Indication(K Units)
  • Table 135. Immunosuppressant Drugs Sales Organ Transplantation , by Region K Units (2015-2020)
  • Table 136. Immunosuppressant Drugs Sales Autoimmune Disorders , by Region K Units (2015-2020)
  • Table 137. Immunosuppressant Drugs Sales Non-autoimmune Inflammatory Diseases , by Region K Units (2015-2020)
  • Table 138. Immunosuppressant Drugs Sales: by Distribution Channel(K Units)
  • Table 139. Immunosuppressant Drugs Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 140. Immunosuppressant Drugs Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 141. Immunosuppressant Drugs Sales Online , by Region K Units (2015-2020)
  • Table 142. Immunosuppressant Drugs Sales Others , by Region K Units (2015-2020)
  • Table 143. Immunosuppressant Drugs Sales: by Drug Class(K Units)
  • Table 144. Immunosuppressant Drugs Sales Corticosteroids , by Region K Units (2015-2020)
  • Table 145. Immunosuppressant Drugs Sales Monoclonal Antibodies (mAbs) , by Region K Units (2015-2020)
  • Table 146. Immunosuppressant Drugs Sales Calcineurin Inhibitors , by Region K Units (2015-2020)
  • Table 147. Immunosuppressant Drugs Sales MTOR Inhibitors , by Region K Units (2015-2020)
  • Table 148. Immunosuppressant Drugs Sales Anti-Proliferative Agents , by Region K Units (2015-2020)
  • Table 149. Immunosuppressant Drugs Sales Others , by Region K Units (2015-2020)
  • Table 150. South America Immunosuppressant Drugs Sales, by Country K Units (2015-2020)
  • Table 151. South America Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 152. South America Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 153. South America Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 154. South America Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 155. Brazil Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 156. Brazil Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 157. Brazil Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 158. Brazil Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 159. Argentina Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 160. Argentina Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 161. Argentina Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 162. Argentina Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 163. Rest of South America Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 164. Rest of South America Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 165. Rest of South America Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 166. Rest of South America Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 167. Asia Pacific Immunosuppressant Drugs Sales, by Country K Units (2015-2020)
  • Table 168. Asia Pacific Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 169. Asia Pacific Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 170. Asia Pacific Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 171. Asia Pacific Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 172. China Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 173. China Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 174. China Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 175. China Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 176. Japan Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 177. Japan Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 178. Japan Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 179. Japan Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 180. India Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 181. India Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 182. India Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. India Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 184. South Korea Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 185. South Korea Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 186. South Korea Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 187. South Korea Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 188. Taiwan Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 189. Taiwan Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 190. Taiwan Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 191. Taiwan Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 192. Australia Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 193. Australia Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 194. Australia Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 195. Australia Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 196. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 197. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 198. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 199. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 200. Europe Immunosuppressant Drugs Sales, by Country K Units (2015-2020)
  • Table 201. Europe Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 202. Europe Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 203. Europe Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 204. Europe Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 205. Germany Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 206. Germany Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 207. Germany Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 208. Germany Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 209. France Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 210. France Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 211. France Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 212. France Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 213. Italy Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 214. Italy Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 215. Italy Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 216. Italy Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 217. United Kingdom Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 218. United Kingdom Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 219. United Kingdom Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 220. United Kingdom Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 221. Netherlands Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 222. Netherlands Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 223. Netherlands Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 224. Netherlands Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 225. Rest of Europe Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 226. Rest of Europe Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 227. Rest of Europe Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 228. Rest of Europe Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 229. MEA Immunosuppressant Drugs Sales, by Country K Units (2015-2020)
  • Table 230. MEA Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 231. MEA Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 232. MEA Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 233. MEA Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 234. Middle East Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 235. Middle East Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 236. Middle East Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 237. Middle East Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 238. Africa Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 239. Africa Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 240. Africa Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 241. Africa Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 242. North America Immunosuppressant Drugs Sales, by Country K Units (2015-2020)
  • Table 243. North America Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 244. North America Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 245. North America Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 246. North America Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 247. United States Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 248. United States Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 249. United States Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 250. United States Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 251. Canada Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 252. Canada Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 253. Canada Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 254. Canada Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 255. Mexico Immunosuppressant Drugs Sales, by End-users K Units (2015-2020)
  • Table 256. Mexico Immunosuppressant Drugs Sales, by Indication K Units (2015-2020)
  • Table 257. Mexico Immunosuppressant Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 258. Mexico Immunosuppressant Drugs Sales, by Drug Class K Units (2015-2020)
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Immunosuppressant Drugs: by End-users(USD Million)
  • Table 270. Immunosuppressant Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 271. Immunosuppressant Drugs Clinics , by Region USD Million (2021-2026)
  • Table 272. Immunosuppressant Drugs Others , by Region USD Million (2021-2026)
  • Table 273. Immunosuppressant Drugs: by Indication(USD Million)
  • Table 274. Immunosuppressant Drugs Organ Transplantation , by Region USD Million (2021-2026)
  • Table 275. Immunosuppressant Drugs Autoimmune Disorders , by Region USD Million (2021-2026)
  • Table 276. Immunosuppressant Drugs Non-autoimmune Inflammatory Diseases , by Region USD Million (2021-2026)
  • Table 277. Immunosuppressant Drugs: by Distribution Channel(USD Million)
  • Table 278. Immunosuppressant Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 279. Immunosuppressant Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 280. Immunosuppressant Drugs Online , by Region USD Million (2021-2026)
  • Table 281. Immunosuppressant Drugs Others , by Region USD Million (2021-2026)
  • Table 282. Immunosuppressant Drugs: by Drug Class(USD Million)
  • Table 283. Immunosuppressant Drugs Corticosteroids , by Region USD Million (2021-2026)
  • Table 284. Immunosuppressant Drugs Monoclonal Antibodies (mAbs) , by Region USD Million (2021-2026)
  • Table 285. Immunosuppressant Drugs Calcineurin Inhibitors , by Region USD Million (2021-2026)
  • Table 286. Immunosuppressant Drugs MTOR Inhibitors , by Region USD Million (2021-2026)
  • Table 287. Immunosuppressant Drugs Anti-Proliferative Agents , by Region USD Million (2021-2026)
  • Table 288. Immunosuppressant Drugs Others , by Region USD Million (2021-2026)
  • Table 289. South America Immunosuppressant Drugs, by Country USD Million (2021-2026)
  • Table 290. South America Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 291. South America Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 292. South America Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 293. South America Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 294. Brazil Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 295. Brazil Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 296. Brazil Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 297. Brazil Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 298. Argentina Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 299. Argentina Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 300. Argentina Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 301. Argentina Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 302. Rest of South America Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 303. Rest of South America Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 304. Rest of South America Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 305. Rest of South America Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 306. Asia Pacific Immunosuppressant Drugs, by Country USD Million (2021-2026)
  • Table 307. Asia Pacific Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 308. Asia Pacific Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 309. Asia Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 310. Asia Pacific Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 311. China Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 312. China Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 313. China Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 314. China Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 315. Japan Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 316. Japan Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 317. Japan Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 318. Japan Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 319. India Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 320. India Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 321. India Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 322. India Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 323. South Korea Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 324. South Korea Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 325. South Korea Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 326. South Korea Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 327. Taiwan Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 328. Taiwan Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 329. Taiwan Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 330. Taiwan Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 331. Australia Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 332. Australia Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 333. Australia Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 334. Australia Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 335. Rest of Asia-Pacific Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 336. Rest of Asia-Pacific Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 337. Rest of Asia-Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 338. Rest of Asia-Pacific Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 339. Europe Immunosuppressant Drugs, by Country USD Million (2021-2026)
  • Table 340. Europe Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 341. Europe Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 342. Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 343. Europe Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 344. Germany Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 345. Germany Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 346. Germany Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 347. Germany Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 348. France Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 349. France Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 350. France Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 351. France Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 352. Italy Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 353. Italy Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 354. Italy Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 355. Italy Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 356. United Kingdom Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 357. United Kingdom Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 358. United Kingdom Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 359. United Kingdom Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 360. Netherlands Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 361. Netherlands Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 362. Netherlands Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 363. Netherlands Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 364. Rest of Europe Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 365. Rest of Europe Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 366. Rest of Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 367. Rest of Europe Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 368. MEA Immunosuppressant Drugs, by Country USD Million (2021-2026)
  • Table 369. MEA Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 370. MEA Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 371. MEA Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 372. MEA Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 373. Middle East Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 374. Middle East Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 375. Middle East Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 376. Middle East Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 377. Africa Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 378. Africa Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 379. Africa Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 380. Africa Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 381. North America Immunosuppressant Drugs, by Country USD Million (2021-2026)
  • Table 382. North America Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 383. North America Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 384. North America Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 385. North America Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 386. United States Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 387. United States Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 388. United States Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 389. United States Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 390. Canada Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 391. Canada Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 392. Canada Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 393. Canada Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 394. Mexico Immunosuppressant Drugs, by End-users USD Million (2021-2026)
  • Table 395. Mexico Immunosuppressant Drugs, by Indication USD Million (2021-2026)
  • Table 396. Mexico Immunosuppressant Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 397. Mexico Immunosuppressant Drugs, by Drug Class USD Million (2021-2026)
  • Table 398. Immunosuppressant Drugs Sales: by End-users(K Units)
  • Table 399. Immunosuppressant Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 400. Immunosuppressant Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 401. Immunosuppressant Drugs Sales Others , by Region K Units (2021-2026)
  • Table 402. Immunosuppressant Drugs Sales: by Indication(K Units)
  • Table 403. Immunosuppressant Drugs Sales Organ Transplantation , by Region K Units (2021-2026)
  • Table 404. Immunosuppressant Drugs Sales Autoimmune Disorders , by Region K Units (2021-2026)
  • Table 405. Immunosuppressant Drugs Sales Non-autoimmune Inflammatory Diseases , by Region K Units (2021-2026)
  • Table 406. Immunosuppressant Drugs Sales: by Distribution Channel(K Units)
  • Table 407. Immunosuppressant Drugs Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 408. Immunosuppressant Drugs Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 409. Immunosuppressant Drugs Sales Online , by Region K Units (2021-2026)
  • Table 410. Immunosuppressant Drugs Sales Others , by Region K Units (2021-2026)
  • Table 411. Immunosuppressant Drugs Sales: by Drug Class(K Units)
  • Table 412. Immunosuppressant Drugs Sales Corticosteroids , by Region K Units (2021-2026)
  • Table 413. Immunosuppressant Drugs Sales Monoclonal Antibodies (mAbs) , by Region K Units (2021-2026)
  • Table 414. Immunosuppressant Drugs Sales Calcineurin Inhibitors , by Region K Units (2021-2026)
  • Table 415. Immunosuppressant Drugs Sales MTOR Inhibitors , by Region K Units (2021-2026)
  • Table 416. Immunosuppressant Drugs Sales Anti-Proliferative Agents , by Region K Units (2021-2026)
  • Table 417. Immunosuppressant Drugs Sales Others , by Region K Units (2021-2026)
  • Table 418. South America Immunosuppressant Drugs Sales, by Country K Units (2021-2026)
  • Table 419. South America Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 420. South America Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 421. South America Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 422. South America Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 423. Brazil Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 424. Brazil Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 425. Brazil Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 426. Brazil Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 427. Argentina Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 428. Argentina Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 429. Argentina Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 430. Argentina Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 431. Rest of South America Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 432. Rest of South America Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 433. Rest of South America Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 434. Rest of South America Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 435. Asia Pacific Immunosuppressant Drugs Sales, by Country K Units (2021-2026)
  • Table 436. Asia Pacific Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 437. Asia Pacific Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 438. Asia Pacific Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 439. Asia Pacific Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 440. China Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 441. China Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 442. China Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 443. China Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 444. Japan Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 445. Japan Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 446. Japan Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 447. Japan Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 448. India Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 449. India Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 450. India Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 451. India Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 452. South Korea Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 453. South Korea Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 454. South Korea Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 455. South Korea Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 456. Taiwan Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 457. Taiwan Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 458. Taiwan Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 459. Taiwan Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 460. Australia Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 461. Australia Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 462. Australia Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 463. Australia Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 464. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 465. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 466. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 467. Rest of Asia-Pacific Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 468. Europe Immunosuppressant Drugs Sales, by Country K Units (2021-2026)
  • Table 469. Europe Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 470. Europe Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 471. Europe Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 472. Europe Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 473. Germany Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 474. Germany Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 475. Germany Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 476. Germany Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 477. France Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 478. France Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 479. France Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 480. France Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 481. Italy Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 482. Italy Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 483. Italy Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 484. Italy Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 485. United Kingdom Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 486. United Kingdom Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 487. United Kingdom Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 488. United Kingdom Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 489. Netherlands Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 490. Netherlands Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 491. Netherlands Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 492. Netherlands Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 493. Rest of Europe Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 494. Rest of Europe Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 495. Rest of Europe Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 496. Rest of Europe Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 497. MEA Immunosuppressant Drugs Sales, by Country K Units (2021-2026)
  • Table 498. MEA Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 499. MEA Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 500. MEA Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 501. MEA Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 502. Middle East Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 503. Middle East Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 504. Middle East Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 505. Middle East Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 506. Africa Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 507. Africa Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 508. Africa Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 509. Africa Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 510. North America Immunosuppressant Drugs Sales, by Country K Units (2021-2026)
  • Table 511. North America Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 512. North America Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 513. North America Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 514. North America Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 515. United States Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 516. United States Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 517. United States Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 518. United States Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 519. Canada Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 520. Canada Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 521. Canada Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 522. Canada Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 523. Mexico Immunosuppressant Drugs Sales, by End-users K Units (2021-2026)
  • Table 524. Mexico Immunosuppressant Drugs Sales, by Indication K Units (2021-2026)
  • Table 525. Mexico Immunosuppressant Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 526. Mexico Immunosuppressant Drugs Sales, by Drug Class K Units (2021-2026)
  • Table 527. Research Programs/Design for This Report
  • Table 528. Key Data Information from Secondary Sources
  • Table 529. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immunosuppressant Drugs: by End-users USD Million (2015-2020)
  • Figure 5. Global Immunosuppressant Drugs: by Indication USD Million (2015-2020)
  • Figure 6. Global Immunosuppressant Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Immunosuppressant Drugs: by Drug Class USD Million (2015-2020)
  • Figure 8. South America Immunosuppressant Drugs Share (%), by Country
  • Figure 9. Asia Pacific Immunosuppressant Drugs Share (%), by Country
  • Figure 10. Europe Immunosuppressant Drugs Share (%), by Country
  • Figure 11. MEA Immunosuppressant Drugs Share (%), by Country
  • Figure 12. North America Immunosuppressant Drugs Share (%), by Country
  • Figure 13. Global Immunosuppressant Drugs: by End-users K Units (2015-2020)
  • Figure 14. Global Immunosuppressant Drugs: by Indication K Units (2015-2020)
  • Figure 15. Global Immunosuppressant Drugs: by Distribution Channel K Units (2015-2020)
  • Figure 16. Global Immunosuppressant Drugs: by Drug Class K Units (2015-2020)
  • Figure 17. South America Immunosuppressant Drugs Share (%), by Country
  • Figure 18. Asia Pacific Immunosuppressant Drugs Share (%), by Country
  • Figure 19. Europe Immunosuppressant Drugs Share (%), by Country
  • Figure 20. MEA Immunosuppressant Drugs Share (%), by Country
  • Figure 21. North America Immunosuppressant Drugs Share (%), by Country
  • Figure 22. Global Immunosuppressant Drugs share by Players 2020 (%)
  • Figure 23. Global Immunosuppressant Drugs share by Players (Top 3) 2020(%)
  • Figure 24. Global Immunosuppressant Drugs share by Players (Top 5) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Astellas Pharma Inc. (Japan) Revenue: by Geography 2020
  • Figure 30. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 32. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer (United States) Revenue: by Geography 2020
  • Figure 34. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 36. Allergan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Allergan, Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 39. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 40. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 42. Veloxis Pharmaceuticals A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 43. Veloxis Pharmaceuticals A/S (Denmark) Revenue: by Geography 2020
  • Figure 44. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 45. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 46. Global Immunosuppressant Drugs: by End-users USD Million (2021-2026)
  • Figure 47. Global Immunosuppressant Drugs: by Indication USD Million (2021-2026)
  • Figure 48. Global Immunosuppressant Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global Immunosuppressant Drugs: by Drug Class USD Million (2021-2026)
  • Figure 50. South America Immunosuppressant Drugs Share (%), by Country
  • Figure 51. Asia Pacific Immunosuppressant Drugs Share (%), by Country
  • Figure 52. Europe Immunosuppressant Drugs Share (%), by Country
  • Figure 53. MEA Immunosuppressant Drugs Share (%), by Country
  • Figure 54. North America Immunosuppressant Drugs Share (%), by Country
  • Figure 55. Global Immunosuppressant Drugs: by End-users K Units (2021-2026)
  • Figure 56. Global Immunosuppressant Drugs: by Indication K Units (2021-2026)
  • Figure 57. Global Immunosuppressant Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 58. Global Immunosuppressant Drugs: by Drug Class K Units (2021-2026)
  • Figure 59. South America Immunosuppressant Drugs Share (%), by Country
  • Figure 60. Asia Pacific Immunosuppressant Drugs Share (%), by Country
  • Figure 61. Europe Immunosuppressant Drugs Share (%), by Country
  • Figure 62. MEA Immunosuppressant Drugs Share (%), by Country
  • Figure 63. North America Immunosuppressant Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis International AG (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Roche Holding AG (Switzerland)
  • Pfizer (United States)
  • Sanofi S.A. (France)
  • Allergan, Inc. (United States)
  • Bristol-Myers Squibb (United States)
  • AbbVie Inc. (United States)
  • Veloxis Pharmaceuticals A/S (Denmark)
  • GlaxoSmithKline plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Rupatadine Comprehensive Study by Type (150 mg Tablets, 300 mg Tablets, Others), Application (Allergic Rhinitis, Urticaria), Dosage (Tablets, Capsules, Syrup), End User (Hospitals, Clinics) Players a...
Rupatadine Comprehensive Study by Type (150 mg Tablets, 300 mg Tablets, Others), Application (Allergic Rhinitis, Urticaria), Dosage (Tablets, Capsules, Syrup), End User (Hospitals, Clinics) Players a...
$ 3800
Pharma Ophthalmic Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores), Therap...
Pharma Ophthalmic Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores), Therap...
$ 3800
Pompe Disease Treatment Comprehensive Study by Type (Infantile-onset Pompe Disease, Adult-Onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End User (Hospitals and Cli...
Pompe Disease Treatment Comprehensive Study by Type (Infantile-onset Pompe Disease, Adult-Onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End User (Hospitals and Cli...
$ 3800
Medicinal Plant Extract Comprehensive Study by Type (Phytomedicines & Herbal Extracts, Flavors & Fragrances, Essential Oils, Spices), Application (Pharmaceuticals & Dietary Supplements, Cosmetics, Fo...
Medicinal Plant Extract Comprehensive Study by Type (Phytomedicines & Herbal Extracts, Flavors & Fragrances, Essential Oils, Spices), Application (Pharmaceuticals & Dietary Supplements, Cosmetics, Fo...
$ 3800
Myocardial Infarction Drugs Comprehensive Study by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, Online Drug Stores), Drug Class (Vasodilators {Nitrodilators, ACE Inhibitors, ARB...
Myocardial Infarction Drugs Comprehensive Study by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, Online Drug Stores), Drug Class (Vasodilators {Nitrodilators, ACE Inhibitors, ARB...
$ 3800
Meningitis Vaccine Comprehensive Study by Type (Meningitis A+C, Meningitis ACWY135, Meningitis B), Application (Medical Care, Healthy, Hospital), Route of Administration (Intramuscular and Subcutaneo...
Meningitis Vaccine Comprehensive Study by Type (Meningitis A+C, Meningitis ACWY135, Meningitis B), Application (Medical Care, Healthy, Hospital), Route of Administration (Intramuscular and Subcutaneo...
$ 4000